Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 4/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | TACR1 | P25103 | 2/20 | 0.34 |
| ▸ | TACR3 | P29371 | 2/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4890372 | 0.95 | P2RY1 (0.37) | P2RY1HDAC1HDAC6EPHX2DRD2 | |
| Trifluoroacetic Acid SCHEMBL4761896 | 0.93 | OPRM1 (0.36) | P2RY1HDAC1HDAC6EPHX2SLC18A3 | |
| SCHEMBL4893251 | 0.89 | P2RY1 (0.36) | P2RY1HDAC1HDAC6EPHX2SLC18A3 | |
| Trifluoroacetic Acid SCHEMBL4881007 | 0.87 | OPRK1 (0.37) | HDAC1HDAC6DRD2SLC18A3SIGMAR1 | |
| SCHEMBL5578587 | 0.86 | SIGMAR1 (0.36) | P2RY1HDAC1HDAC6EPHX2SLC18A3 | |
| SCHEMBL4821789 | 0.85 | P2RY1 (0.39) | P2RY1HDAC1HDAC6EPHX2 | |
| SCHEMBL4759951 | 0.83 | SLC18A3 (0.39) | HDAC1HDAC6DRD2SLC18A3SIGMAR1 | |
| SCHEMBL5579105 | 0.82 | OPRM1 (0.42) | P2RY1SIGMAR1OPRM1 | |
| SCHEMBL4893344 | 0.81 | OPRM1 (0.41) | HDAC1HDAC6EPHX2SIGMAR1FFAR1 | |
| SCHEMBL4761770 | 0.81 | EPHX2 (0.43) | EPHX2DRD2FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200491-A1 | 1,2-Dihydro-Spiro[3H-Indole-3,4'-Piperidine] Compounds, as Modulators of the Mas Receptor Novel | ARENA PHARMACEUTICALS, INC. | 2008-08-21 | — | — | US | disclosed |
| EP-1899339-A1 | 1,2-DIHYDRO-SPIRO(3H-INDOLE-3-4 -PIPERIDINE) COMPOUNDS AS MODULATORS OF THE MAS RECEPTOR NOVEL | Arena Pharmaceuticals, Inc. (US) | 2008-03-19 | — | — | EP | disclosed |
| WO-2007002114-A1 | 1,2-DIHYDRO-SPIRO(3H-INDOLE-3-4’-PIPERIDINE) COMPOUNDS AS MODULATORS OF THE MAS RECEPTOR NOVEL | ARENA PHARMACEUTICALS, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200491-A1 | 1,2-Dihydro-Spiro[3H-Indole-3,4'-Piperidine] Compounds, as Modulators of the Mas Receptor Novel | AGTR1, AGTR2, AVPR2 | P2RY1 205/4885HDAC1 418/4885HDAC6 835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.